Effectiveness of allogeneic bone marrow transplantation in patients with acute leukemia in complete remission and in patients with chronic myeloid leukemia during the chronic phase

• Published in: Terapevtic̆eskii arhiv Vol. 71; no. 7; p. 27
• Main Authors: Liubimova, L S, Savchenko, V G, Mendeleeva, L P, Kliasova, G A, Gribanova, E O, Demidova, I A, Gal'tseva, I V, Kuz'mina, L A, Momotiuk, K S, Kuliev, R G
• Format: Journal Article
• Language: Russian
• Published: Russia (Federation) 1999
• Subjects: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating - therapeutic use; Bone Marrow Transplantation; Child; Cyclophosphamide - therapeutic use; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia - mortality; Leukemia - therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy; Male; Middle Aged; Radiotherapy Dosage; Remission Induction; Time Factors; Transplantation Conditioning; Whole-Body Irradiation
• ISSN: 0040-3660

To study clinical efficiency of allogenic bone marrow transplantation (ABMT) in patients with acute leukemia (AL) in the first remission and in patients with chronic myeloid leukemia (CML) in chronic phase; to analyse overall and recurrence-free survival in relation to the diagnosis and age. 26 patients with AL and 24 ones with CML (29 males and 21 females) were subjected to ABMT within 10 last years. Median of age in AL and CML was 24.5 and 25.5 years, median of the time since the diagnosis was 9 and 13 months, respectively. Follow-up since the ABMT made up 67.5 months (31-107) and 38 months (6-108), respectively. Conditioning was made with cyclophosphamide (120 mg/kg) plus total radiation of the body (12 Gy) in 16 patients, myelosan (mileran) in a dose 16 mg/kg plus cyclophosphane (120 mg/kg) in 34 patients. The marrow was taken from HLA-identical sibs, enzygotic twins (5 recipients). Cytogenetic investigations were made in CML. The retention of the transplant was controlled by immunological and molecular tests. Among AL patients 50% are still alive. Probability of 80-month survival reached 55%, 110 months--42%. Probable recurrence-free survival was 78%. All the patients are in a complete clinico-hematological remission. Among CML patients 75% are still alive. Of them 89% had a complete hematological remission, 72% are in a complete hematological and cytogenetic remission. Probable 110 month survival equals 75%, probability to survive without recurrence--52%. Early lethality (100 days) of toxic and infectious complications was as low as 10 and 6%, respectively. Frequency of lethal acute secondary disease was under 8%. ABMT made in AL patients during the first complete remission and in CML patients in the chronic phase brings about very good results which are much better than after routine cytostatic chemotherapy.